Epigenetic Biomarkers for Alzheimer's Disease

Completed

• Conditions: Alzheimer Disease

• Registration Number: NCT04081285
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay.

The objective of this study is to improve our understanding of the risk factors of LOAD by conducting an epigenome wide study within patients of LOAD contrasted against their cognitively normal siblings.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-07-23
• Study Start: 2019-09-01
• Study First Submitted QC: 2019-09-04
• Study First Posted: 2019-09-09
• Primary Completion: 2024-11-30
• Study Completion: 2024-11-30
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-25
• Last Update Posted: 2025-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Sufficient Cantonese competency for cognitive test
• Written informed consent given
• Have at least one gender-matched cognitively normal sibling

Exclusion Criteria

• Subjects who refuse blood taking procedure
• Do not have a reliable family/caregiver informant (personal contact at least once a month)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DNA methylation	5 years
RNA-seq microbiome	5 years
Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog)	5 years

Trial Locations

Locations (1)

The Chinese University of Hong Kong; 🇭🇰 Hong Kong, Hong Kong